<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810796</url>
  </required_header>
  <id_info>
    <org_study_id>HRanTrop</org_study_id>
    <nct_id>NCT01810796</nct_id>
  </id_info>
  <brief_title>Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial</brief_title>
  <official_title>Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Working hypothesis and aims: 1) To explore the pathophysiology of postoperative troponin
      elevations and 2) whether ranolazine, a new anti-ischemic drug that has no effect on blood
      pressure or heart rate, prevents postoperative myocardial injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-risk patients undergoing non cardiac surgery will be randomized to receive either
      Ranolazine or placebo perioperatively and troponin will be measured on the first 3 days after
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative troponin</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Artery Disease,</condition>
  <arm_group>
    <arm_group_label>Ranolazine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine 500-1000mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine versus placebo</description>
    <arm_group_label>Ranolazine treatment</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients age 18 and above, undergoing major surgery that require at least 24 hours
        (overnight) stay in the post anesthesia care unit (PACU) or intensive care unit (ICU), and
        who either have known history of CAD or at least 3 of the following Revised Cardiac Risk
        Index (RCRI) criteria29F17: 1) high-risk type of surgery, 2) history of ischemic heart
        disease, 3) history of congestive heart failure, 4) history of cerebrovascular disease, 5)
        diabetes mellitus, 6) renal failure (creatinine &gt; 2mg/ml).

        Exclusion Criteria:

          -  Pregnancy, LV ejection fraction â‰¤35%, patients with severe valvular disease, patients
             with poor echocardiographic images, patients who cannot swallow the pill after
             surgery, refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giora Landesberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giora Landesberg, Assoc. Prof.</last_name>
    <phone>97226777269</phone>
    <email>gio@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah - Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giora Landesberg, Assoc. Prof.</last_name>
      <phone>97226777269</phone>
      <email>gio@cc.huji.ac.il</email>
    </contact>
    <investigator>
      <last_name>Giora Landesberg, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Giora Landesberg</investigator_full_name>
    <investigator_title>Associate Profesor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

